Development of In-vitro Assays to Estimate Rabies Viral Protein

Image

Journal of Vaccines & Vaccination is an Open access Journal publishing articles on Human Vaccine Trials, Veterinary Vaccines, Cancer Vaccines, Vaccine Adjuvants, Vaccine regulatory issues, Preclinical vaccine studies, Childhood vaccines, HIV vaccines, Malaria vaccines, TB vaccines. The research article entitled: Development of In-vitro Assays to Estimate Rabies Viral Protein in Vaccine Preparation which discusses the vaccine preparation of rabies.

Vaccine against rabies is prepared by cell culture technology and these vaccines are free from many side effects when compared to nerve tissue vaccines. The vaccine production is a continuous process involving propagation of virus, harvesting, concentration, inactivation, purification, and formulation with preservatives. The quantification of viral protein in the intermediate biological product is an in-process quality control test to reduce product loss during the various processes of vaccine manufacturing. The conventional in-vivo & in-vitro tests employed for the quantification of rabies viral protein are time-consuming, laborious and requires laboratory animals. In this study, we attempted to develop in-house serological methods such as sandwich ELISA, Dot Blot for the detection and quantification of rabies antigen in the intermediate biological material during vaccine preparation. The hyper immune sera were prepared by immunizing two animal models i.e. Guinea Pigs and rabbits with standard Rabies antigen. The sera samples were purified by saturated ammonium sulphate precipitation and further by G50 gel column. The antirabies antibody titre in the purified preparation was estimated using Rapid Fluorescent Focus Inhibition Test (RFFIT). National Reference Rabies Vaccine received from Central Drug Laboratory, Kasauli was used to prepare the local reference standard and it was included in the in-house serological methods to validate the assay. Our in-house tests are found to be simple, rapid and cost effective and require less time when compared to in-vivo animal challenge and cell culture-based in-vivo tests.

Detection and quantification of the viral protein in the intermediate biological product is a very crucial step and it is helpful to reduce the product loss during the vaccine manufacturing. The in-house serological methods developed by us can be used for the detection and quantification of rabies antigens in intermediate biological products during vaccine preparation and also it can be implemented to test the potency of the final vaccine after due validation of these assay protocols. In comparison to conventional methods, our in-house methods are simple, cost-effective, rapid and no animal facility and no cell culture facilities are required.

Readers/authors can express their opinion, queries to us and our journal accepting the articles for the upcoming issue. Authors can submit their manuscripts directly to online submission.  

Thanks & Regards,
John Kimberly
Editorial Manager
Journal of Vaccines & Vaccination
Email: jvv@scholarlypub.com